Abstract

The work of the Vaccine Production Core encompasses efforts in three inter-related areas: live, recombinant vector development; novel adjuvant development; and protein production. The efforts that will be pursued in vector and adjuvant development by this CHAVI group will be described. A rationale for pursuing each technology, the work accomplished to date in developing that technology, and the immediate plans for further development of that technology will be described. This CHAVI group will begin to advance the most promising of these technologies into human clinical testing as early as the second year of the funding period. The protein production component of this core will serve the Haynes RO1, the Shaw SLG project, the Sodroski SLG project, and the Structural Biology Core D. Specifically, we will pursue work in the following areas: 1. Live, recombinant vector development a. Recombinant chimeric adenovirus b. Recombinant mycobacteria c. Recombinant vesicular stomatitis virus 2. Novel adjuvant development a. Polymers b. Chemoattractant cytokines c. TLR agonists 3. Recombinant protein production

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI067854-01
Application #
7127923
Study Section
Special Emphasis Panel (ZAI1-CL-A (M1))
Project Start
2005-07-14
Project End
2012-06-30
Budget Start
2005-07-14
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$1,214,090
Indirect Cost

  Institution

Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928
Yates, Nicole L; deCamp, Allan C; Korber, Bette T et al. (2018) HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol 92:
Pardi, Norbert; Hogan, Michael J; Porter, Frederick W et al. (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17:261-279
Boelen, Lies; Debebe, Bisrat; Silveira, Marcos et al. (2018) Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol 3:
Prévost, Jérémie; Richard, Jonathan; Medjahed, Halima et al. (2018) Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. J Virol 92:
Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:
Liu, Donglai; Wang, Chu; Hora, Bhavna et al. (2017) A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology 14:46
Pacheco, Beatriz; Alsahafi, Nirmin; Debbeche, Olfa et al. (2017) Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol 91:
Marks, Florian; von Kalckreuth, Vera; Aaby, Peter et al. (2017) Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 5:e310-e323
Matoga, Mitch M; Hosseinipour, Mina C; Aga, Evgenia et al. (2017) Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. Antivir Ther 22:205-213

Showing the most recent 10 out of 309 publications